Delivering on the next mRNA-based breakthroughs

2:15 PM - 3:15 PM (PDT), Monday, June 13, 2022 ・ Upper Level, Session Room 3

With the delivery of mRNA-based COVID-19 vaccines, mRNA earned its rightful place among the leading modalities for biopharmaceutical innovation. The flexibility and versatility of mRNA has marked a turning point in the R&D work on this platform with an opportunity to transform outcomes in many areas of need for patients across viral infections, rare genetic diseases, cancer, immunoinflammatory conditions, and even cardiovascular disease. This panel will discuss the scientific opportunity and efforts underway to improve on the delivery and design of mRNA-based vaccines and therapeutics.

Sponsored By
Moderator
photo
Senior Science Editor
GEN
Speakers
photo
Pfizer Inc.
photo
Chief Executive Officer
Serina Therapeutics, Inc.
photo
CEO
Scribe Therapeutics
photo
Director of Business Development
ExploRNA Therapeutics
photo
CEO
Replicate Bioscience, Inc.